Defense Verdict Returned In Testosterone Replacement Therapy Heart Attack Trial
Mealey's (August 20, 2021, 9:57 AM EDT) -- CHICAGO — An Illinois federal jury on Aug. 17 returned a defense verdict for Actavis Inc. in a testosterone replacement therapy (TRT) heart attack case in which the plaintiff opted out...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login